Sirolimus safe and well tolerated in wet AMD patients

MacuSight has announced positive preliminary data from the Phase I study of its lead product candidate for wet age-related macular degeneration (AMD), sirolimus.

MacuSight has announced positive preliminary data from the Phase I study of its lead product candidate for wet age-related macular degeneration (AMD), sirolimus.

As part of the randomized, open-label study of 30 patients, investigators evaluated the safety, tolerability and biological activity of sirolimus when delivered by either subconjunctival or intravitreal injection. The results of the study showed no evidence of increased intraocular pressure, inflammatory response to treatment or indication of progression of cataracts. Furthermore, the study provided a preliminary assessement of the drug's biological activity in AMD, with patients demonstrating improvements in visual acuity despite extended duration of disease prior to entering the study. In addition to this, patients also experienced anatomical improvements as demonstrated by a reduction in retinal thickness.

The findings also demonstrate that sirolimus, administered via subconjunctival injection, is as effective, if not more so, than sirolimus administered via intravitreal injections. This is good news for physicians and patients since subconjunctival injections are regarded as less invasive.

MacuSight is currently preparing to intitiate a Phase II trial.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Related Content
© 2023 MJH Life Sciences

All rights reserved.